Thursday, March 19 - Breakfast

A Medical Forum for Evidence, Experience, and Interactive Dialogue on Contemporary Considerations in Hemophilia Care

Sponsored By: Sanofi

7:00 - 8:00 AM, B113-114
Hemophilia care is entering a transformative era, with growing emphasis on how clinical approaches can support the individual needs and treatment goals of patients. Join leading experts and peers for a dynamic and educational program featuring interactive dialogue across a range of topics, including case-based scenarios, evolving management strategies, and the broader aspirations of people living with hemophilia. This forum will provide real-world perspectives and practical insights from clinical practice, fostering thoughtful, balanced discussion to support healthcare professionals in considering a range of evidence-based strategies as they collaborate with patients in today’s changing therapeutic environment.

Presenters:
Moderator: Tami Singleton, MD
Dr. Singleton is a pediatric hematologist/oncologist at Ochsner Health in New Orleans, and Chief Science Officer at the American Thrombosis and Hemostasis Network. She completed her medical degree at Louisiana State University and fellowship training programs at Johns Hopkins School of Medicine and Tulane University. Dr. Singleton’s practice includes pediatric and adolescent bleeding and clotting disorders and sickle cell disease. She is a member of the National Bleeding Disorders Foundation Medical and Scientific Advisory Board

Panelists:
Mindy Simpson, MD
Dr. Simpson is a pediatric hematologist/oncologist at Rush University in Chicago, IL where she is director of the Rush Hemophilia and Thrombophilia Center and Assistant Professor of Pediatrics. She completed her medical degree at Temple University and fellowship training at Children’s Hospital of Colorado. Her primary practice and research interests are in pediatric bleeding and clotting disorders, and she has participated in numerous clinical trials.

Angela Weyand, MD
Dr. Weyand is a pediatric hematologist and Associate Professor of Pediatrics at the University of Michigan. Dr. Weyand completed her medical degree and fellowship training at the University of Michigan. Her clinical focus is women and girls with bleeding or clotting disorders and is co-director of a combined hematology/gynecology program serving this population. She is active in many national and international professional organizations focusing on gender equity in blood disorders
Submit Pre-Conference Questions Here .

 

Advancing Hemophilia Care Through TFPI Inhibition: Clinical Evidence and Emerging Real-World Experience With Hympavzi (marstacimab)

Sponsored By: Pfizer Inc

7:00 - 8:00 AM, B115-116
Non‑factor therapies continue to reshape the treatment landscape for hemophilia by offering novel approaches to rebalancing coagulation. Hympavzi (marstacimab), a subcutaneously administered anti‑TFPI therapy, represents an important new option informed by both robust clinical data and emerging real‑world experience.

This symposium will explore the scientific rationale, mechanism of action, clinical trial evidence, and practical considerations surrounding the use of Hympavzi (marstacimab) in hemophilia management. Faculty will review the foundational science behind Hympavzi (marstacimab) and summarize key findings from the Phase 3 clinical development program.

In addition, the session will feature a discussion with hematologists who have real‑world experience integrating Hympavzi (marstacimab) into clinical practice. Their perspectives on patient selection, breakthrough bleeds, surgical data, monitoring, and initial outcomes will provide attendees with practical insights into how Hympavzi (marstacimab) may be incorporated into the evolving therapeutic landscape of hemophilia care.

---

Thursday, March 19 - Lunch

Gene Therapy in Hemophilia B: A Journey of Innovation and Impact

Sponsored By: CSL

11:45 AM - 12:45 PM, B113-114
Gene Therapy in Hemophilia B: A Journey of Innovation and Impact” is a dynamic symposium hosted by leading hematology experts to investigate the evolution of gene therapy in hemophilia B, review five-year durability data from the HOPE-B trial, and share real-world clinical insights. This interactive session will also highlight a powerful patient story that brings the promise of gene therapy to life. This symposium provides an opportunity to deepen your understanding of transformative treatment approaches and explore considerations for the future for gene therapy in hemophilia B.

 

Real-World Management of Hemophilia A and B: Clinical Cases with Rebalancing and Factor Replacement Therapies

Sponsored By: Sanofi

11:45 AM - 12:45 PM, B110-112

Join an interactive, poster-style session where leading experts present real-world patient cases managed with Sanofi’s portfolio of therapies for hemophilia A and B. Learn how personalized treatment strategies are applied in clinical practice from your peers.

Presenters:
Erin Cockrell, DO
HTC Director, St. Joseph’s Hospital Center for Bleeding & Clotting Disorders
Dr. Erin Cockrell grew up in Northeast Ohio and graduated from The Ohio State University with a BS in Biology and Ohio University College of Osteopathic Medicine with a degree in Osteopathic Medicine. She completed residency in internal medicine and pediatrics at Akron Children’s Hospital, Akron, Ohio and pediatric hematology/oncology fellowship at Case Western Reserve University, Cleveland, Ohio. She worked as a pediatric hematologist/oncologist at Akron Children’s Hospital and served as co-director of the Young Women’s Bleeding Center. In 2013 she moved to Tampa, Fl and is now one of the pediatric hematology/oncology physicians at St. Joseph’s Children’s Hospital. She is also the Director of St. Joseph’s Hospitals Center for Bleeding and Clotting Disorders.

Jonathan C. Roberts, MD
Associate Medical & Research Director, Bleeding & Clotting Disorders Institute
Assistant Professor of Pediatrics, University of Illinois College of Medicine
Jonathan C. Roberts, MD is the Associate Medical & Research Director at the Bleeding & Clotting Disorders Institute (BCDI) and Assistant Professor of Pediatrics at the University of Illinois College of Medicine at Peoria in Peoria, IL, USA.

Dr. Roberts graduated from the Southern Illinois School of Medicine in 2008 and completed his internship and residency in Pediatrics at the University of Illinois College of Medicine at Peoria at OSF St. Francis Children’s Hospital in 2011. After finishing his residency, Dr. Roberts completed a fellowship in Pediatric Hematology/Oncology/Blood & Marrow Transplantation at the Medical College of Wisconsin/Children’s Hospital of Wisconsin in 2014 and worked as a post-doctoral fellow at the Blood Center of Wisconsin Blood Research Institute.

Dr. Roberts’ research areas of interest are in advancing novel laboratory assay development to improve the diagnosis of von Willebrand Disease and to enhance individualized clinical management of hemophilia.

Maissaa Janbain, MD
Associate Professor of Clinical Medicine Tulane - Hemophilia Care Center Associate Director, Louisiana Center for Bleeding and Clotting Disorders
Dr. Maissaa Janbain is currently an Associate Professor of Clinical Medicine and the Associate Director of the Louisiana Center for bleeding and clotting disorders. She has received multiple awards and grants, including the National Hemophilia Foundation Fellowship Award (2014), Louisiana Clinical and Translational Research Roadmap Scholarship (2015), HTRS Mentored Research Award (2017), and School of Medicine Scientist Pipeline Program (2017), which allowed her to focus her research and time on taking care of patients with benign hematologic disorders, especially hemophilia and thrombosis and platelet disorders. Dr. Janbain has presented her research at several national and international meetings and has published in multiple journals.

Doris Quon, MD, PhD
Medical Director, Orthopaedic Hemophilia Treatment Center, Los Angeles, California
Doris Quon is a hematologist in Los Angeles, California. She is affiliated with Santa Monica-UCLA & Orthopedic Hospital and Saint John’s Health Center.
She received her MD and PhD from the David Geffen School of Medicine at UCLA and completed her internship and residency in Internal Medicine as well as fellowship in Hematology-Oncology at UCLA School of Medicine. Since finishing her fellowship in 2003, she has been with the Orthopedic Hemophilia Treatment Center.

Exploring a Subcutaneous Treatment Option in Hemophilia Care with HYMPAVZI (marstacimab-hncq)

Sponsored By: Pfizer, Inc.

11:45 AM - 12:45 PM, B115-116

Session will include a presentation on HYMPAVZI (marstacimab-hncq): the mechanism of action, key clinical trial data, administration guidelines, and patient cases followed by an audience Q&A.
Speaker: Dr. Craig Kessler

---

Thursday, March 19 - Dinner

Rethinking hemophilia A management: balancing bleed protection and administration considerations

Sponsored by: Novo Nordisk

5:30 - 6:30 PM, B115-116
Despite advancements in hemophilia A management, trade-offs remain: patients often choose between compromising bleed protection or accepting administration-related challenges. This program will reveal real-world data on these unspoken challenges and discuss strategies to identify barriers and enable more effective shared decision-making.

 

Bridging the Gaps: Scientific Updates in ITP, iTTP, and wAIHA

Sponsored By: Sanofi

5:30 - 6:30 PM, B113-114
Immune-mediated hematologic disorders—including Immune Thrombocytopenic Purpura (ITP), warm Autoimmune Hemolytic Anemia (wAIHA), and immune Thrombotic Thrombocytopenic Purpura (iTTP)—present significant diagnostic and therapeutic challenges in contemporary hematology practice. This symposium addresses the most recent updates in immune-mediated hematologic disorders.

Presenters:
Sandhya Panch, MD, MPH
Dr. Panch is an Associate Professor of Hematology at the University of Washington School of Medicine and the Medical Director of Transfusion at the Fred Hutch Cancer Center. She completed her hematology, oncology, and transfusion medicine fellowship at the National Institutes of Health (NIH). She also holds a Master of Public Health in Epidemiology and Biostatistics from the University of Minnesota. Dr. Sandhya Panch is committed to the pursuit of clinical and translational studies in the areas of hematology and transfusion medicine. She also serves on the medical advisory board for the WAIHA warriors.

Camila Masias, MD, MPH
Dr. Masias is a clinician and clinical investigator at Miami Cancer Institute – Baptist Health South Florida, where she also is an assistant professor of hematology at Florida International University (FIU). She completed her hematology and oncology fellowship at The Ohio State university, where she also completed a master’s in public health with an emphasis in clinical and translational research. Her primary clinical and research interests include diagnosis and treatment of thrombotic microangiopathies, where she has authored numerous peer-reviewed journal articles. She values the role of a classical hematologist in the hospital, in improving process and developing cost-effective strategies for better patient care. She currently chairs the ASH system-based hematology and implementation subcommittee and is a member of the ASH Committee on Quality.